Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Reviews

Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma

Edward Wolfgang Lee, Sarah Khan

Clin Mol Hepatol. 2017;23(4):265-272. Published online November 8, 2017

Web of Science 38 Crossref 36

DOI: https://doi.org/10.3350/cmh.2017.0111

Treatment options after sorafenib failure in patients with hepatocellular carcinoma

Imane El Dika, Ghassan K. Abou-Alfa

Clin Mol Hepatol. 2017;23(4):273-279. Published online November 20, 2017

Web of Science 29 Crossref 29

DOI: https://doi.org/10.3350/cmh.2017.0108

Contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS) 2017 – a review of important differences compared to the CT/MRI system

Tae Kyoung Kim, Seung Yeon Noh, Stephanie R Wilson, Yuko Kono, Fabio Piscaglia, Hyun-Jung Jang, Andrej Lyshchik, Christoph F. Dietrich, Juergen K. Willmann, Alexander Vezeridis, Claude B Sirlin

Clin Mol Hepatol. 2017;23(4):280-289. Published online September 15, 2017

Web of Science 91 Crossref 94

DOI: https://doi.org/10.3350/cmh.2017.0037

Imaging evaluation of non-alcoholic fatty liver disease: focused on quantification

Dong Ho Lee

Clin Mol Hepatol. 2017;23(4):290-301. Published online October 10, 2017

Web of Science 100 Crossref 99

DOI: https://doi.org/10.3350/cmh.2017.0042

Histopathological evaluation of liver fibrosis and cirrhosis regression

Regina C. Lo, Haeryoung Kim

Clin Mol Hepatol. 2017;23(4):302-307. Published online December 20, 2017

Web of Science 92 Crossref 87

DOI: https://doi.org/10.3350/cmh.2017.0078

Editorials

Use of sofosbuvir in chronic kidney disease: Is it necessary?

Tae Seop Lim, Sang Hoon Ahn

Clin Mol Hepatol. 2017;23(4):308-310. Published online September 26, 2017

Web of Science 4 Crossref 6

DOI: https://doi.org/10.3350/cmh.2017.0109

Is it possible to predict the development of an entecavir resistance mutation in patients with chronic hepatitis B in clinical practice?

Joon Yeul Nam, Jeong-Hoon Lee

Clin Mol Hepatol. 2017;23(4):311-313. Published online December 4, 2017

DOI: https://doi.org/10.3350/cmh.2017.0069

Lamivudine: fading into the mists of time

Jonggi Choi, Young-Suk Lim

Clin Mol Hepatol. 2017;23(4):314-315. Published online November 28, 2017

DOI: https://doi.org/10.3350/cmh.2017.0110

Original Articles

Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function

Hyun Phil Shin, Ji-Ae Park, Blaire Burman, Richard A. Kozarek, Asma Siddique

Clin Mol Hepatol. 2017;23(4):316-322. Published online August 22, 2017

Web of Science 12 Crossref 16

DOI: https://doi.org/10.3350/cmh.2016.0087

Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience

Hong Joo Kim, Yong Kyun Cho, Woo Kyu Jeon, Byung Ik Kim

Clin Mol Hepatol. 2017;23(4):323-330. Published online September 5, 2017

Web of Science 7 Crossref 11

DOI: https://doi.org/10.3350/cmh.2017.0005

Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B

Kwan Sik Lee, Young-Oh Kweon, Soon-Ho Um, Byung-Ho Kim, Young Suk Lim, Seung Woon Paik, Jeong Heo, Heon-Ju Lee, Dong Joon Kim, Tae Hun Kim, Young-Sok Lee, Kwan Soo Byun, Daeghon Kim, Myung Seok Lee, Kyungha Yu, Dong Jin Suh

Clin Mol Hepatol. 2017;23(4):331-339. Published online September 26, 2017

Web of Science 14 Crossref 10

DOI: https://doi.org/10.3350/cmh.2016.0040

Case Report

Complete response of advanced hepatocellular carcinoma to sorafenib : another case and a comprehensive review

Tae Suk Kim, Ji Hoon Kim, Baek hui Kim, Young-Sun Lee, Yang Jae Yoo, Seong Hee Kang, Sang-June Suh, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun

Clin Mol Hepatol. 2017;23(4):340-346. Published online June 20, 2017

Web of Science 18 Crossref 19

DOI: https://doi.org/10.3350/cmh.2016.0070

Viewed By 4810	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 4734	MAFLD: How is it different from NAFLD?
Viewed By 4637	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4380	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 4292	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 214	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 155	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 133	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 116	MAFLD: How is it different from NAFLD?
Cited By 94	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Previous issues